SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Year: 2019
Type: article
Source: Annals of Oncology
Institutions: The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Cancer Center Hospital East, Institute of Clinical Cancer Research, Seoul National University, Seoul National University Hospital, University of Chicago, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Georgetown University Medical Center, MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center, Leipzig University, Weill Cornell Medicine, Universitair Ziekenhuis Leuven, KU Leuven, Sun Yat-sen University, Sun Yat-sen University Cancer Center, Astellas Pharma (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, AstraZeneca, Gilead Sciences, Celgene, Merck KGaA, Taiho Pharmaceutical, BeiGene, Incyte, MacroGenics, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Astellas Pharma, Vifor Pharma, Servier, Ono Pharmaceutical, Ipsen, Medac, Genentech, Astellas Pharma Global Development, Chugai Pharmaceutical, Daiichi Sankyo Europe
OpenAlex ID: W2990042561